Loading
medac
medac is a German family-owned pharmaceutical company whose alkylating agent treosulfan, long used in Europe, was approved by the FDA in 2025 as conditioning treatment before stem cell transplantation in acute myeloid leukaemia and myelodysplastic syndromes.
Also called: medac GmbHmedac Pharma
Overview
medac GmbH, based in Wedel near Hamburg, is a privately held German company specialising in haematology, oncology, urology and autoimmune disease. Its alkylating agent treosulfan, approved in Europe for decades and marketed there as Trecondi for transplant conditioning, received FDA approval in January 2025 (Grafapex) with fludarabine as a preparative regimen before allogeneic haematopoietic stem cell transplantation in adults and children with acute myeloid leukaemia or myelodysplastic syndromes. Company facts are from the official website and FDA approval records.
Headquarters
Wedel, DE
Scorecard
All companies#211of 1245 companies, score 25
- approved products +6
- modalities +2
- regions +3
- registry trials +14
1 approved, 0 in phase 3, 0 earlier, 0 targets, 51 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Products
1ApprovedAlkylating conditioning agent (busulfan analogue)
Treosulfan · Grafapex
A conditioning chemotherapy given before donor stem-cell transplant in AML and MDS; it was long used in Europe and reached the US in 2025.
Connected
6Similar pages
- CompanyGamida Cell
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag fda-oce-applicant.
- CompanyGeron Corporation
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag fda-oce-applicant.
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- PersonMarc H.G.P. Raaijmakers
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TreatmentARD103
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TargetSLX4
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
cancers
fronts
drugs
ApprovedAlkylating conditioning agent (busulfan analogue)
Treosulfan · Grafapex
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
medac.de · 1
US Food and Drug Administration · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Add Wikidata ids and Wikipedia links for 80 more companies · diff · file
Sourced, not expert-reviewed